NEW YORK, January 13, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Actavis plc (NYSE: ACT), ResMed Inc. (NYSE: RMD), West Pharmaceutical Services, Inc. (NYSE: WST), Sirona Dental Systems Inc. (NASDAQ: SIRO), and Theravance Inc. (NASDAQ: THRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Actavis plc Research Report
On January 8, 2014, Actavis plc (Actavis) announced that the US Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis®. Actavis stated that it plans to launch the product immediately. According to the Company, it is eligible for 180 days of generic market exclusivity for being the "first applicant" to submit a substantially complete ANDA. In a separate release dated January 6, 2014, the Company announced that it will host an Investor Meeting on January 31, 2014 in New York at 8:00 a.m. EST, which will be webcast simultaneously. Actavis stated that the meeting, to be hosted by its executive leadership team, will provide an overview of 2013 executional results, growth initiatives and an in-depth look at the Company with regard to the acquisition of Warner Chilcott plc in 2013, including latest financial forecast. The Company added that a question-and-answer session will be held following the presentations. The Full Research Report on Actavis plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ResMed Inc. Research Report
On December 18, 2013, ResMed Inc. (ResMed) reported that it will release its results for the Q2 FY 2014 and H1 FY 2014 (period ended December 31, 2013) on January 23, 2014 after 1:00 p.m. PT. The Company stated that it will hold a conference call on the same day at 1:30 p.m. PT, which will be webcast on its website under Investors section, to review its results, market trends, and future outlook. ResMed added that an online archive of the broadcast will be available approximately 30 minutes after the live call and will remain available for two weeks. The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
West Pharmaceutical Services, Inc. Research Report
On January 8, 2014, West Pharmaceutical Services, Inc.'s (West Pharmaceutical) stock climbed 1.44%, ending the day at $49.93. Over the previous three trading sessions, shares of West Pharmaceutical rose 1.65%, compared to the Dow Jones Industrial Average, which declined 0.04% during the same period. The Full Research Report on West Pharmaceutical Services, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Sirona Dental Systems Inc. Research Report
On January 8, 2014, Sirona Dental Systems Inc.'s (Sirona Dental Systems) stock declined 0.32%, ending the day at $69.12. Over the previous three trading sessions, shares of Sirona Dental Systems fell 0.39%, compared to the Nasdaq Composite which increased 0.82% during the same period. The Full Research Report on Sirona Dental Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Theravance Inc. Research Report
On January 8, 2014, Theravance Inc.'s (Theravance) stock increased 1.62%, ending the day at $36.91. Over the previous three trading sessions, shares of Theravance rose 1.48%, compared to the Nasdaq Composite which climbed 0.82% during the same period. The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner